As shown in FigureS3, HCC patients in high-risk group were more sensitive to antivascular drugs such as A.770,041, AICAR, AKT.inhibitor.VIII, while patients in low-risk group were more sensitive to ABT.888, AG.014699, ATRA. Here, AKT1 is linked to hepatocellular carcinoma.